Delivering the Future: FedEx Unveils Autonomous Delivery Robot
FedEx Corp. (NYSE:FDX) announced today a development in cutting-edge delivery solutions to meet the rapidly changing needs of consumers — the FedEx SameDay Bot — an autonomous delivery device designed to help retailers make same-day and last-mile deliveries to their customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190227005421/en/
FedEx SameDay Bot (Photo: Business Wire)
With the bot, retailers will be able to accept orders from nearby customers and deliver them by bot directly to customers’ homes or businesses the same day. FedEx is collaborating with companies such as AutoZone, Lowe’s, Pizza Hut, Target, Walgreens and Walmart to help assess retailers’ autonomous delivery needs. On average, more than 60 percent of merchants’ customers live within three miles of a store location, demonstrating the opportunity for on-demand, hyper-local delivery.
“The FedEx SameDay Bot is an innovation designed to change the face of local delivery and help retailers efficiently address their customers’ rising expectations,” said Brie Carere, executive vice president and chief marketing and communications officer for FedEx. “The bot represents a milestone in our ongoing mission to solve the complexities and expense of same-day, last-mile delivery for the growing e-commerce market in a manner that is safe and environmentally friendly.”
The FedEx bot is being developed in collaboration with DEKA Development & Research Corp. and its founder Dean Kamen, inventor of many life-changing technologies, including the iBot™ Personal Mobility Device and the Segway®.
“The bot has unique capabilities that make it unlike other autonomous vehicles,” Kamen said. “We built upon the power base of the iBot, an advanced, FDA-approved, mobility device for the disabled population with more than 10 million hours of reliable, real-world operation. By leveraging this base in an additional application, we hope that the iBot will become even more accessible to those who need it for their own mobility.”
The FedEx bot is designed to travel on sidewalks and along roadsides, safely delivering smaller shipments to customers’ homes and businesses. Bot features include pedestrian-safe technology from the iBot, plus advanced technology such as LiDAR and multiple cameras, allowing the zero-emission, battery-powered bot to be aware of its surroundings. These features are coupled with machine-learning algorithms to detect and avoid obstacles, plot a safe path and allow the bot to follow road and safety rules. Proprietary technology makes the bot highly capable, allowing it to navigate unpaved surfaces, curbs, and even steps for an extraordinary door-to-door delivery experience.
FedEx plans to test the bot this summer in select markets, including Memphis, Tenn., pending final city approvals.
“We couldn’t be more excited that FedEx chose its hometown as one of the pilot cities for this revolutionary innovation,” Mayor Jim Strickland, City of Memphis, said. “We look forward to working with FedEx to continue introducing technologies that will help improve the quality of life in our community.”
The initial test will involve deliveries between selected FedEx Office locations. FedEx Office currently offers a SameDay City service that operates in 32 markets and 1,900 cities using branded FedEx vehicles and uniformed FedEx employees. The FedEx bot will complement the FedEx SameDay City service.
“The FedEx SameDay Bot represents the next chapter in our long legacy of delivering innovation and outstanding service, supported by an already existing FedEx logistics ecosystem,” said Brian Philips, President and CEO of FedEx Office. “We are excited to bring this technology to address new markets and better support our customers. The companies who have provided feedback on its potential use have been instrumental in ensuring we are looking toward the future of e-commerce.”
The FedEx bot will support retailers in several segments, and the first group of retail customers to view the prototype have recognized the value the technology can bring to their industries.
“We are thrilled to be working with the talented teams at FedEx and DEKA on this revolutionary innovation,” said Bill Rhodes, Chairman, President and CEO, Customer Satisfaction, AutoZone. “When we saw the FedEx SameDay Bot in action, it confirmed to our team the many ways it can help us improve our service by offering reliable, highly efficient deliveries to our customers.”
“The convenience and capability of the FedEx Same Day Bot has the potential to greatly simplify and speed distribution for the full range of our customers. Consider pros who could save time and money by never leaving the job site for the critical tools and supplies they need from Lowe’s,” said Don Frieson, Lowe’s Executive Vice President, Supply Chain. “We look forward to exploring all the possibilities to enhance the service we provide our customers through this innovation.”
“Pizza Hut is constantly exploring new technology-based solutions to advance our delivery business as we look to redefine the modern pizza experience for our customers,” said Nicolas Burquier, chief customer and operations officer, Pizza Hut, U.S. “The opportunity to work with a proven innovator in the delivery space like FedEx allows us the opportunity to leverage cutting-edge technology to further optimize our best-in-class delivery experience.”
“We continue to invest in new technologies and capabilities that make Target the easiest place to shop – both now and in the future. We’re excited to be collaborating with FedEx to explore how autonomous robots could enhance delivery services and more, ensuring we continue to exceed our guests’ expectations for ease and convenience,” said John Mulligan, chief operating officer, Target.
“At Walgreens, we’re on a journey to leverage the latest in innovative technologies to provide a differentiated pharmacy and health care experience, and delivery solutions that bring our services to our customers wherever they are and whenever they need them,” said Alex Gourlay, co-chief operating officer, Walgreens Boots Alliance, Inc. “With FedEx as a partner, Walgreens has become the fastest choice for next-day prescription delivery in the U.S., and we’re excited that through our growing relationship, the FedEx SameDay Bot is another way we can offer better service and greater convenience to our customers.”
The bot made its first public appearance during NBC’s The Tonight Show Starring Jimmy Fallon on Tuesday, Feb. 26. This prototype will be refined to meet safety standards and regulations, and the specific needs of customers. For more information on the FedEx SameDay Bot, please visit thefuturefedex.com. For b-roll, please click here.
About FedEx Corp.
FedEx Corp. (NYSE:FDX) provides customers and businesses worldwide with a broad portfolio of transportation, e-commerce and business services. With annual revenues of $69 billion, the company offers integrated business applications through operating companies competing collectively and managed collaboratively, under the respected FedEx brand. Consistently ranked among the world’s most admired and trusted employers, FedEx inspires its more than 450,000 team members to remain “absolutely, positively” focused on safety, the highest ethical and professional standards and the needs of their customers and communities. To learn more about how FedEx connects people and possibilities around the world, please visit about.fedex.com.
About DEKA Research & Development Corp.
Based in Manchester, NH, DEKA is a research and development company of nearly 600 employees comprised of engineering, manufacturing and quality assurance professionals focused on the development of new technologies that span a diverse set of applications. The company was founded in 1982 by Dean Kamen, an inventor who holds more than a thousand U.S. and foreign patents and numerous awards, many of them for innovative medical devices that have expanded the frontiers of healthcare worldwide.
Certain statements in this press release may be considered forward-looking statements, such as management’s expectations regarding the capabilities of and efficiencies available through the FedEx SameDay Bot, and our ability to satisfy applicable safety standards and regulations and receive required government approvals. Such forward-looking statements are subject to risks, uncertainties and other factors, including inherent uncertainty that accompanies new and innovative technology, unexpected results from the initial tests, and evolving safety standards, regulations and required government approvals, which could cause actual results to differ from results expressed or implied by such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made. We do not undertake or assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190227005421/en/
Contact information
Bonny Harrison
FedEx Media Relations
901.434.5207
bonny.harrison@fedex.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom